Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Diffusion Pharmaceuticals. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Diffusion Pharmaceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
Diffusion Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.
Unable to determine if Diffusion Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Diffusion Pharmaceuticals's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Diffusion Pharmaceuticals's finances.
The net worth of a company is the difference between its assets and liabilities.
Diffusion Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Diffusion Pharmaceuticals's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Diffusion Pharmaceuticals's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Diffusion Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. David G. Kalergis, JD, MBA, is Co-Founder of Diffusion Pharmaceuticals Inc.(formerly known as Diffusion Pharmaceuticals, LLC) and serves as its Chairman since January 2016 and Chief Executive Officer since 2004. Mr. Kalergis has overall responsibility for implementing the Diffusion's strategy, as established by the Board of Directors, as well as handling day-to-day operational matters. Mr. Kalergis served as the Chairman of the Board and Chief Executive Officer at Restorgenex Corporation since January 08, 2016. From 1986 to 1990, Mr. Kalergis served as the President and General Counsel of Designs Import/Export, Ltd. From 1991 to 1997, he served as General Counsel, Director of Business Development and Consultant to Pharmaceutical Research Associates, Inc. He serves as a Director of University of Virginia Gateway. He serves as an Director of Diffusion Pharmaceuticals Inc.(formerly known as Diffusion Pharmaceuticals, LLC.) since January 2016. Mr. Kalergis's duties at Gateway began on February 1, 1998. He serves on the board of the Virginia Piedmont Technology Council and the Computers4Klds Program. He served as a Director of Virginia National Bank and Virginia National Bankshares Corporation. From 1982 to 1986, he was associated with the New York law firm of Dewey, Ballantine, Bushby, Palmer & Wood. In 2002, he was awarded the Virginia Piedmont Technology Council's "Navigator" award for his leadership and contributions to the technology community and the region's economic development. He is a Member of the New York and Virginia State Bar Associations and is the author of The Role of the University in the Commercialization of Biotechnology (1981). Mr. Kalergis is a graduate of the Harvard Business School's Leadership and Strategy in Biotechnology and Pharmaceuticals program. Mr. Kalergis graduated from the University of Virginia with a BA degree in Psychology in 1970. In 1982, he received J.D. and M.B.A. degrees from the University of Virginia.
David's compensation has been consistent with company performance over the past year.
David's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Diffusion Pharmaceuticals management team is about average.
Chief Financial Officer
Director of Project Management
Senior Medical Advisor
Vice President of Clinical Operations
Senior Consultant for Manufacturing
Senior Consultant - Regulatory Affairs
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Diffusion Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. Its lead product candidate is transcrocetinate sodium, which has initiated Phase 3 trials for the treatment of glioblastoma multiforme (GBM); Phase 2 clinical trials for the treatment of pancreatic cancer; Phase 2/3 clinical trials for the treatment of metastatic brain cancer; and Phase 2 trial for the treatment of stroke. The company is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of age-related macular degeneration; and is in pre-clinical development stage for the treatment of oncology primarily GBM. Diffusion Pharmaceuticals Inc. was founded in 2001 and is headquartered in Charlottesville, Virginia.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.